Tristel PLC (TSNLF)
ValueMarkers Composite Index
17% below intrinsic value ($0)
Tristel PLC (TSNLF) — VMCI valuation read
Composite valuation read on TSNLF: VMCI 58/100 against a Healthcare sector median of 50. The 8-point above-median print is the headline number for Tristel PLC, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for TSNLF: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on TSNLF: TSNLF trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of 2.9x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
TSNLF rose 2.0% over the trailing 7 days, with a -15.5% read on a 30-day basis.
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.